Expression of \( p53 \) in Cisplatin-resistant Ovarian Cancer Cell Lines: Modulation with the Novel Platinum Analogue (\( 1R, 2R\)-Diaminocyclohexane)(\( trans \)-diacetato)(dichloro)platinum(IV)\(^1 \)

George S. Hagopian, Gordon B. Mills, Abdul R. Khokhar, Robert C. Bast, Jr., and Zahid H. Siddik\(^2 \)

Departments of Gynecologic Oncology [G. S. H.], Molecular Oncology [G. B. M.], and Clinical Investigation [A. R. K., R. C. B., Z. H. S.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

ABSTRACT

The compound (\( 1R, 2R\)-diaminocyclohexane)(\( trans \)-diacetato)(dichloro)platinum(IV) (DACH-acetato-Pt) is a novel platinum-based antitumor agent with clinical potential against cisplatin-resistant disease. In our laboratory, we evaluated the cytotoxicity of cisplatin and DACH-acetato-Pt in a panel of cisplatin-resistant ovarian tumor models with differing \( p53 \) status. Cisplatin was relatively more effective against mutant or null \( p53 \) cell lines (continuous drug exposure \( I_C_{50} \), 1.2–3.3 \( \mu M \)) than it was against those harboring wild-type \( p53 \) (\( I_C_{50} \), 2.8–9.9 \( \mu M \)). In contrast, DACH-acetato-Pt was considerably more active in wild-type \( p53 \) models (\( I_C_{50} \), 0.17–1.5 \( \mu M \)) than it was in mutant or null models (\( I_C_{50} \), 2.7–11.3 \( \mu M \)). Inactivation of wild-type \( p53 \) function in OVCA-429 cells by the human papillomavirus type 16 (HPV 16) E6 plasmid increased resistance to DACH-acetato-Pt by 2–5-fold, which confirmed the drug's dependence in OVCA-429 cells, induction of \( p53 \) by the two agents was severely attenuated, and corresponding increases in \( p21^{Waf1/Cip1} \) were abrogated. This suggests that \( p21^{Waf1/Cip1} \) increases were \( p53 \) dependent. Collectively, the results demonstrate that DACH-acetato-Pt is very distinct from cisplatin. In particular, the greater activity of DACH-acetato-Pt in cisplatin-resistant wild-type \( p53 \) ovarian tumor models can be ascribed to its ability to more efficiently induce \( p53 \) protein and activate \( p53 \) functions.

INTRODUCTION

Ovarian cancer is the most lethal gynecological malignancy in the United States; in 1997, it was predicted that 26,800 women would develop the disease, and \( \sim 14,200 \) women would die that year (1). Although a number of factors impact on prognosis, including age, histological type and grade, tumor DNA content, extent of disease at presentation, and volume of residual disease, the most important is International Federation of Gynecology and Obstetrics stage (2). The 5-year survival rates for stages I, II, III, and IV are 74, 58, 30, and 19%, respectively (3). Unfortunately, 75% of women present with advanced disease (stages III and IV; Ref. 4). Current therapy for advanced disease consists of staging laparotomy and cytoreductive surgery (5), followed by chemotherapy with platinum-containing complexes and Taxol (2, 6). Despite initially encouraging response rates of up to 70%, most women develop recurrent disease (7). Thus, given the high response rate and the low 5-year survival rate, cisplatin resistance is a critically important factor that limits the clinical utility of this agent.

In view of the central problem of cisplatin resistance, efforts have focused on the development of alternative platinum-based analogues that can be more effective against resistant disease. The compound DACH-acetato-Pt,\(^3 \) which bears axial acetate ligands (Fig. 1), represents a novel class of plati-
num-based antitumor agents. The ability of DACH-acetato-Pt to circumvent resistance acquired through exposure to cisplatin is a particularly important observation of our laboratory (8), and mechanistic studies have been in progress as part of its preclinical development for the anticipated clinical trials.

Although the molecular basis of drug sensitivity and resistance is complex, the p53 tumor suppressor protein appears to play a major role in modulating cellular response to therapeutic agents. However, the impact of p53 gene status on chemo- and radiosensitivity varies between different tumor types. This is a function of (a) the integrity of the cellular transduction pathways of the cell activated in response to injury, (b) the specific type of cellular damage produced by the drug, and (c) the inherent cell-specific responses of the particular cell (9). In cells that are programmed for apoptosis (especially hematopoietic and lymphoid cells), loss of p53 function decreases their sensitivity to a wide variety of DNA-damaging agents (10–17). This, however, is not observed in other cell types (18, 19). Presence of wild-type p53, on the other hand, does not necessarily ensure a chemosensitive phenotype, and a recent clinical study has underscored this very convincingly: Righetti et al. (20) reported that, among the group of chemoresistant ovarian tumors, 37% had wild-type p53 and 63% had mutant p53. It is also noteworthy that, contrary to expectations, inactivation of wild-type p53 in MCF-7 breast carcinoma cells and in normal human foreskin fibroblasts enhanced sensitivity of these specific cells to cisplatin and other selected chemotherapeutic agents (21, 22).

This study was undertaken to assess the extent of cisplatin resistance in established human ovarian cancer lines with wild-type, mutant, or null p53 status and to examine whether p53 status modulates the ability of DACH-acetato-Pt to circumvent this resistance. We report here that, against cisplatin-resistant tumor cells with wild-type p53, DACH-acetato-Pt was significantly more effective and, unlike cisplatin, caused these cells to arrest in G1 in a p53-dependent manner.

**MATERIALS AND METHODS**

**Chemicals.** Cisplatin was synthesized by us using a standard procedure reported previously (23). We have reported the synthesis and chemical characterization of DACH-acetato-Pt separately (24). Cisplatin and DACH-acetato-Pt were dissolved in normal saline and water, respectively, then sterilized through 0.22-μm disc filters. The concentration of each drug was confirmed by its platinum metal content, as determined by flameless atomic absorption spectroscopy (25), and then the drugs were diluted to 2 mM stock solutions. MTT was purchased from Sigma Chemical Co. (St. Louis, MO), and FCS was obtained from BioWhittaker, Inc. (Walkersville, MD).

**Cell Lines.** The nine ovarian carcinoma cell lines used in this study were established from biopsies taken from patients who had failed cisplatin- and/or alkylating agent-based chemotherapy and were classified as cisplatin resistant (26–30). The p53 statuses of these cell lines have been documented (31–33) and are indicated in Table 1. Cells were grown as monolayers in 5% CO₂ and 95% humidified air at 37°C. The OVCA-420, -429, -432, and -433 cell lines were maintained in Eagle’s MEM with Earle’s salts containing 10% heat-inactivated FCS, 1 mM l-glutamine, 1 mM sodium pyruvate, 1 mM nonessential amino acids, and antibiotics (100 μg/ml streptomycin and 100 units/ml penicillin). The SKOV-3 cell line was grown in McCoy’s 5a medium, 15% heat-inactivated FCS, and 2 mM l-glutamine. The HEY, OCC1, OVCAR-3, and OVCAR-10 cell lines were maintained in RPMI 1640 containing 10% heat-inactivated FCS, and 2 mM l-glutamine. The McCoy’s 5a medium and RPMI 1640 were both supplemented with an antibiotic cocktail (100 μg/ml streptomycin, 100 units/ml penicillin, and 100 μg/ml neomycin).

**HPV 16 E6 Transfection Studies.** The HPV 16 E6 gene was cloned into a pCMV plasmid that also contains a neomycin gene (34). This plasmid and the pCMV-neo control vector were obtained from Dr. K. R. Cho (Johns Hopkins University School of Medicine, Baltimore, MD). For transfections, 1 × 10⁶ OVCA-429 cells were seeded in a 100-mm tissue culture dish and incubated until 50–80% confluent. The HPV 16 E6 gene (34) or the pCMV-neo control vector were introduced into cells using Lipofectamine (Life Technologies, Inc.). Approximately 14 days later, G418-resistant colonies were selected and expanded.

The clones were examined for their stable growth characteristics and/or expression of p53. The HPV 16 E6 protein facilitates the degradation of the p53 protein via the ubiquitin-dependent proteolytic pathway (35). Therefore, a reduced level of p53 protein by Western analysis was used as an indication of clones with positive HPV 16 E6-mediated effects. Three such E6 clones were selected, along with two control transfectants, for experimental investigations. These selected clones were maintained in complete Eagle’s MEM supplemented with 800 μg/ml G418. The clones were cultured in G418-free medium for one passage prior to undertaking experiments.

**Cytotoxic Evaluations.** Cytotoxicity was determined by a modified MTT assay (36), which has been validated against...
the clonogenic assay in the evaluation of new platinum compounds (37). Cells in exponential growth were trypsinized, counted using a hemocytometer, and then diluted to appropriate concentrations. Aliquots (100 μl) of cell suspensions were added to each well of a 96-well microtiter plate. The stock cisplatin or DACH-acetato-Pt solution was serially diluted with complete medium immediately before use. Each diluted solution (100 μl) was added to wells in triplicate, and the cells were incubated at a 37°C in a 5% CO₂ humidified incubator. After 3 or 5 days, when untreated control cells were in logarithmic growth, 50–200 μl of culture medium or cisplatin or DACH-acetato-Pt solution in medium were added to wells in triplicate. After 2 h to cisplatin or DACH-acetato-Pt, as described above, the cells were washed and reincubated in drug-free medium. At completion of each set of experiments. Before analysis, the cell suspension was thawed, washed once with ice-cold PBS, resuspended in a solution of propidium iodide (10 μg/ml) in PBS containing 0.5% Tween 20 and 500 units/ml of RNase A (Sigma) and incubated at room temperature for 30 min and then at 4°C overnight. Cell cycle kinetics were determined on a Becton Dickinson flow cytometer.

**Western Analysis.** Cells were exposed for 2 h to cisplatin or DACH-acetato-Pt as described above, washed, and incubated at 37°C in drug-free medium for 24 h. The cells were then washed with PBS and lysed for 10 min on ice with 1 ml of lysis buffer [50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.02% sodium azide, 1% NP40, 0.1% SDS, 0.5% sodium deoxycholate, 100 μg/ml phenylmethylsulfonyl fluoride, and 1 μg/ml aprotinin]. The lysates were collected by microcentrifugation at 4°C overnight. Cell cycle kinetics were determined on a Becton Dickinson flow cytometer.

### Table 2 IC₅₀ of cisplatin and DACH-acetato-Pt in wild-type, mutant, and null p53 ovarian cancer cell lines following continuous or 2-h drug exposures

<table>
<thead>
<tr>
<th>Cell line</th>
<th>Continuous drug exposure</th>
<th>2-h drug exposure</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Cisplatin</td>
<td>DACH-acetato-Pt</td>
</tr>
<tr>
<td>Wild-type p53</td>
<td>2.93 ± 0.18°</td>
<td>1.49 ± 0.24</td>
</tr>
<tr>
<td>OVCA-420</td>
<td>4.10 ± 0.63</td>
<td>0.79 ± 0.10</td>
</tr>
<tr>
<td>OVCA-429</td>
<td>9.90 ± 2.86</td>
<td>1.07 ± 0.33</td>
</tr>
<tr>
<td>OVCA-433</td>
<td>8.90 ± 1.77</td>
<td>0.17 ± 0.01</td>
</tr>
<tr>
<td>OVCAR-10</td>
<td>2.78 ± 0.23</td>
<td>0.45 ± 0.05</td>
</tr>
<tr>
<td>Mutant or null p53</td>
<td>2.03 ± 0.25</td>
<td>11.3 ± 2.08</td>
</tr>
<tr>
<td>OVCA-432</td>
<td>1.22 ± 0.33</td>
<td>2.65 ± 0.76</td>
</tr>
<tr>
<td>OVCAR-3</td>
<td>3.30 ± 0.92</td>
<td>9.85 ± 3.65</td>
</tr>
<tr>
<td>OCC1</td>
<td>1.32 ± 0.17</td>
<td>3.18 ± 0.57</td>
</tr>
<tr>
<td>SKOV-3</td>
<td>3.16 ± 0.26</td>
<td>6.61 ± 2.65</td>
</tr>
</tbody>
</table>

° Mean ± SE; n = 3–5.

Statistical Analysis. Differences between groups were evaluated by Student’s t test and were considered significant for values of P < 0.05.
RESULTS

Cytotoxicity of Cisplatin and DACH-acetato-Pt. Cytotoxic evaluations were conducted in nine cisplatin-resistant ovarian cancer cell lines of differing p53 status (Table 1), and the results are shown in Table 2. Using the continuous drug exposure protocol, we found the IC_{50} for cisplatin in the wild-type p53 cell lines to be in the range of 2.78–9.9 μM, with a median value of 4.1 μM. The IC_{50} for the mutant/null p53 cell lines, on the other hand, ranged from 1.22 to 3.3 μM, with a median of ~1.32–2.03 μM. Thus, cisplatin was more effective against mutant/null p53 cell lines than against the wild-type p53 lines. With DACH-acetato-Pt, the median IC_{50} in wild-type p53 cell lines was 0.79 μM (range, 0.17–1.49 μM). The median value increased to 3.18–9.85 μM (range, 2.65–11.3 μM) in mutant/null p53 cell lines. It is apparent, therefore, that wild-type p53 cell lines were more sensitive to DACH-acetato-Pt than mutant/null p53 cell lines. This relationship is in sharp contrast to that seen with cisplatin. The differential cytotoxic profile of cisplatin and DACH-acetato-Pt is readily apparent by examining the ratio of IC_{50} for the two agents (Table 2). This ratio was >1 in wild-type p53 cell lines and <1 in the mutant/null p53 models. The difference between the ratios was statistically significant (P < 0.05), and this further demonstrates the superior activity of DACH-acetato-Pt in wild-type p53 cell lines. Similar results were obtained when drug exposure to cells was limited to 2 h (Table 2). However, the IC_{50} for cisplatin and DACH-acetato-Pt following pulse exposures were 8.1-fold (SE, 0.83) and 13.0-fold (SE, 3.3) greater, respectively, than those following continuous drug exposures. These increases in IC_{50} for the 2-h exposure were expected and were similar to the 9–10-fold increases reported in human ovarian tumor models for cisplatin (29) and DACH-Pt(IV) analogues (37).

To confirm the role of wild-type p53 in mediating the superior cytotoxic activity of DACH-acetato-Pt, we established stable transfectants of the OVCA-429 cell line with the HPV 16 E6 plasmid to inactivate p53 function. The results with the control PVC1 and the test E6B2 clones indicate that loss of p53 function significantly increased resistance to DACH-acetato-Pt by ~3–5-fold (P < 0.05; Table 3). In contrast, no changes in resistance to cisplatin were noted.

Cell Cycle Kinetics following Exposure to Cisplatin and DACH-acetato-Pt. To gain insights into the mechanism of action of DACH-acetato-Pt, cell cycle studies were performed with two tumor models. With both wild-type p53 OVCA-433 and mutant p53 OVCA-432 cell lines, IC_{50} concentrations of cisplatin arrested cells in G2 (Fig. 2, A and C): by 36–48 h, most of the cells were in G2-M. In contrast, equitoxic concentrations of DACH-acetato-Pt demonstrated an interesting p53-dependent differential effect on cell cycle kinetics. In the OVCA-343 model with wild-type p53, the analogue arrested cells in G1, with a concomitant decrease in the S-phase population (Fig. 2B). The kinetic profile returned to normal by 48 h. No accumulation in G1 was observed in mutant p53 OVCA-432 cells exposed to DACH-acetato-Pt. Instead, the analogue behaved like cisplatin and maximally arrested cells in G2-M by 48 h (Fig. 2D). In these resistant tumor cell lines, associations between G2-M arrest and low cytotoxicity of the analogue and between G1 arrest and high activity are apparent.

Whether the G1 arrest in wild-type p53 cells by DACH-acetato-Pt was mediated in a p53-dependent manner was examined in wild-type p53 OVCA-429 parental cells and its control and E6 transfectant clones. In parental cells, cisplatin induced the characteristic G2-M arrest by 24–48 h and a concomitant decrease in the G1 population (Fig. 3A). This was similar to the effect seen in OVCA-432 and -433 cells (Fig. 2, A and C). DACH-acetato-Pt caused OVCA-429 cells to arrest in G1 and a decrease in S-phase (Fig. 3B), which is consistent with observations made with OVCA-433 cells (Fig. 2B). The effect of equitoxic concentrations of cisplatin and DACH-acetato-Pt on cell cycle distribution of control transfectant PVA1 and PVC1 clonal cells were similar to those observed in parental cells (Fig. 4). However, the characteristic G1 arrest produced by DACH-acetato-Pt was abrogated by the HPV 16 E6 plasmid in the three E6 clones (E6B2, E6B4, and E6C6; Fig. 4A). Indeed, there were no gross differences between cisplatin and the analogue with regard to distribution of E6 transfectant cells in G1, S, or G2-M (Fig. 4). The results indicate that the presence of wild-type p53 is important for DACH-acetato-Pt to mediate cellular effects with greater potency.

p53 and p21^{WAF1/CIP1} Induction by Cisplatin and DACH-acetato-Pt. To investigate why cisplatin-resistant ovarian cancer cells with wild-type p53 were sensitive to DACH-acetato-Pt, we examined p53 induction by the platinum agents in selected models. Increases in p21^{WAF1/CIP1} were also determined as an indication of the transactivation potential of the p53-dependent waf1/cip1 gene and to correlate with the G1 arrest induced by DACH-acetato-Pt. The mutant p53 OVCA-432 cells, which overexpress p53, demonstrated no detectable changes in p53 protein levels 24 h after a 2-h exposure to equitoxic concentrations of cisplatin (up to 80 μM) or DACH-

---

Table 3  IC_{50} of cisplatin and DACH-acetato-Pt in control clone PVC1 and HPV E6 clone E6B2 from OVCA-429 cells and corresponding resistance factors for E6B2

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Continuous drug exposure</th>
<th>2-h drug exposure</th>
</tr>
</thead>
<tbody>
<tr>
<td>IC_{50} PVC1</td>
<td>6.41 ± 0.83c</td>
<td>1.04 ± 0.17</td>
</tr>
<tr>
<td>IC_{50} E6B2</td>
<td>6.73 ± 1.54</td>
<td>2.55 ± 0.58c</td>
</tr>
<tr>
<td>Resistance factor</td>
<td>1.03 ± 0.19</td>
<td>3.25 ± 1.11d</td>
</tr>
</tbody>
</table>

a Resistance factor of E6B2 = (IC_{50}, E6B2)/(IC_{50}, PVC1).

b Mean ± SE; n = 3–7.

c Significantly different from PVC1 (P < 0.05).
d Significantly different from 1.00 (P < 0.05).
acetato-Pt (up to 400 μM; data not shown). Levels of p21\textsuperscript{Waf1/Cip1} were undetectable in these cells before or after drug treatment. The wild-type p53 OVCA-429 cell line also expressed detectable basal levels of p53, with coordinate increases in p21\textsuperscript{Waf1/Cip1}, was only observed in OVCA-429 cells at the high concentration of 125 μM (~5× IC\textsubscript{50}). In comparison, DACH-acetato-Pt increased levels of both p53 and p21\textsuperscript{Waf1/Cip1} at the lower drug concentration of 5 μM (~IC\textsubscript{50}). Interestingly, the increases in p21\textsuperscript{Waf1/Cip1} were only observed in parallel with p53 induction, which suggests that the induced p53 was functional with regard to its ability to transactivate the \textit{waf1/cip1} gene. Similar differential effects of cisplatin and the analogue on p53 induction were also seen in wild-type p53 OVCA-433 tumor cells (data not shown). Thus, the greater cytotoxicity of DACH-acetato-Pt against cisplatin-resistant ovarian tumor cells with wild-type status may relate to its ability to induce p53 and p21\textsuperscript{Waf1/Cip1} expression.

To explain the reduction in cytotoxicity of DACH-acetato-Pt by E6, levels of p53 and p21\textsuperscript{Waf1/Cip1} were also examined in the control PVC1 and E6-transfectant E6B2 clones of OVCA-429 cells. Compared to parental OVCA-429 cells, untreated PVC1 cells expressed ~1.5-fold greater levels of p53 and 2.4-fold greater levels of p21\textsuperscript{Waf1/Cip1} (Fig. 6). As with parental cells, cisplatin increased p53 by ~30% in PVC1 cells at the high 125 μM drug concentration only. Surprisingly, there was no corresponding increase in p21\textsuperscript{Waf1/Cip1}, which may be due to selective desensitization of transactivation mechanisms by the increased basal expression of p53 in the PVC1 clone. DACH-acetato-Pt, on the other hand, induced both p53 and p21\textsuperscript{Waf1/Cip1} in PVC1 cells at a lower drug concentration (Fig. 6), and this was consistent with results obtained in parental cells (Fig. 5). However, increases in p53 and p21\textsuperscript{Waf1/Cip1} were lower, and this again may be related to higher basal levels of these proteins in the control transfectant. In contrast, the E6 plasmid reduced basal levels of p53 in E6B2 clone by ~30% compared to parental OVCA-429 cells but had no effect on p21\textsuperscript{Waf1/Cip1} levels (Fig. 6). Both cisplatin and DACH-acetato-Pt failed to induce p53 or p21\textsuperscript{Waf1/Cip1} in this clone. The results indicate that E6 abrogates drug-induced up-regulation of p53 and p21\textsuperscript{Waf1/Cip1}, and this is consistent with cytotoxicity and cell cycle data obtained with the analogue from the E6B2 transfectant.

**DISCUSSION**

The initial reports on the activity of cisplatin were made three decades ago by Rosenberg et al. (38, 39). Since that time, analogue development has been a major priority and has centered on both improving the toxicity profile of cisplatin and circumventing cisplatin resistance (40). Our efforts have resulted in the identification of DACH-acetato-Pt as an analogue with clinical potential against cisplatin-resistant disease (8). This study reveals that this analogue is selectively active in cisplatin-resistant ovarian tumor cells harboring wild-type p53.

The presence of wild-type p53 in tumor cells generally correlates with a good clinical response to drug therapy (41). The cytotoxic effect is usually preceded by drug-mediated cellular accumulation of wild-type p53. This induction can activate p53, which can then transactivate a number of genes to regulate cell cycle and apoptosis. The p53-dependent transactivation of p21\textsuperscript{Waf1/Cip1} gene, for instance, appears to be essential in arresting cells in G\textsubscript{1} of the cell cycle. The p53-dependent expression of the \textit{bax} gene, on the other hand, triggers apoptosis as a facile cytotoxic response to chemotherapeutic agents. Not surprisingly, loss of apoptotic functions appears to be a major cause of resistance to cytotoxic drugs (42–44). Consistent with this understanding is our observation here that cisplatin-resistant ovarian cells harboring wild-type p53 were resistant to induction of p53 by cisplatin, whereas the greater cytotoxicity of DACH-
acetato-Pt in these cells was associated with significant induction of p53 and p21Waf1/Cip1. Furthermore, the analogue was considerably less cytotoxic against cisplatin-resistant cells with mutant p53. The demonstration of a loss in the activity of DACH-acetato-Pt in the wild-type p53 OVCA-429 cell line expressing HPV 16 E6, which inactivates the p53 protein via a ubiquitin-dependent pathway (34, 35, 45), confirms the significant role of wild-type p53 and its induction in the cytotoxicity of the analogue. In contrast, the lack of change in the cytotoxicity of cisplatin in the E6 transfectant clone provides credence to the idea that p53 does not participate in mediating the cytotoxic effect of cisplatin in the OVCA-429 model.

The differential molecular and associated cytotoxic effects of cisplatin and DACH-acetato-Pt in resistant wild-type p53 ovarian tumor cell lines are novel observations among platinum antitumor agents. The explanation for the results is not currently known but may be reconciled by considering that the two platinum drugs activate independent signal transduction pathways in response to DNA damage. It is likely that the normal pathway used by cisplatin in resistant wild-type p53 ovarian cells is down-regulated, which prevents the characteristic induction of p53 and p21Waf1/Cip1 proteins in response to DNA damage by clinically relevant concentrations of cisplatin. DACH-acetato-Pt, on the other hand, may use an alternative pathway that appears to be intact and fully capable of regulating p53 levels in response to DNA damage. The existence of alternative pathways for p53 induction has been implicated previously from studies with ataxia-telangiectasia cells. Artuso et al. (46) and Zhang et al. (47), for instance, reported that p53 induction was poor following treatment with ionizing radiation but was comparable to that in normal cells treated with methylmethane sulfonate, cisplatin, or UV light. Similarly, we have found in a separate study that the cisplatin-resistant ovarian 2780CP model lacked the ability to accumulate p53 in response to cisplatin, but induction of p53 and p53-mediated functions was normal when cells were exposed to X-rays (48). On the basis of these results, it may be reasonable to speculate that methylmethane sulfonate, cisplatin, and UV light activate sig-

Fig. 4 The effects of cisplatin or DACH-acetato-Pt on cell cycle kinetics of three HPV 16 E6 clones (E6B2, E6B4, and E6C6) and two control vector clones (PV A1 and PV C1) derived from the wild-type p53 OVCA-429 cell line. Attached cells in an exponential-growth phase were exposed for 2 h to drug vehicle (control), 25 μM cisplatin, or 5 (control clones) or 25 (E6 clones) μM DACH-acetato-Pt. The cells were then washed and reincubated in drug-free medium. Cells were harvested at 24 h and analyzed by flow cytometry. A, G1; B, S phase; C, G2-M.

Fig. 5 Induction of p53 and p21Waf1/Cip1 in the wild-type p53 OVCA-429 cell line exposed to cisplatin or DACH-acetato-Pt. Cells in exponential growth phase were exposed to 0–125 μM of cisplatin or DACH-acetato-Pt (DACH-ac-Pt) for 2 h, washed and then incubated in drug-free medium. Cells were harvested 24 h later, and protein was extracted and examined for p53 and p21Waf1/Cip1 levels by Western blotting. A, immunoblot analysis of p53 and p21Waf1/Cip1. B, levels of p53 (relative to control in Lane 1 or 5) estimated from immunoblots by laser densitometry. C, levels of p21Waf1/Cip1 (relative to control in Lane 1 or 5) estimated from immunoblots by laser densitometry.
Fig. 6 Induction of p53 and p21\textsuperscript{Waf1/Cip1} by cisplatin or DACH-acetato-Pt in the HPV 16 E6 clone E6B2 and the control vector PVC1 clone derived from the wild-type p53 OVCA-429 cell line. Cells in exponential growth phase were exposed to 0, 25, or 125 \(\mu\text{M}\) cisplatin or DACH-acetato-Pt (DACH-ac-Pt) for 2 h, washed, and then incubated in drug-free medium. Cells were harvested 24 h later, and protein was extracted and examined for p53 and p21\textsuperscript{Waf1/Cip1} levels by Western blotting. A, immunoblot analysis of p53 and p21\textsuperscript{Waf1/Cip1} for the PVC1 clone. B, immunoblot analysis of p53 and p21\textsuperscript{Waf1/Cip1} for the E6B2 clone. C, levels of p53 relative to those in parental OVCA-429 cells (relative to \textit{Lanes 1}) estimated from immunoblots by laser densitometry. D, levels of p21\textsuperscript{Waf1/Cip1} (relative to \textit{Lanes 1}) estimated from immunoblots by laser densitometry.

Current therapy for effective management of ovarian carcinoma consists of cytoreductive surgery (5), followed by combination chemotherapy with platinum complexes and Taxol (6). Nevertheless, the 5-year survival rate of this disease is still dismal and has not changed significantly over the past 10 years (59). These statistics may change, however, as we begin to more fully comprehend the existence of multiple drug-specific signaling pathways and then use chemotherapeutic agents to activate specific pathways for affecting tumor cell kill. In this regard, the possibility that an alternative p53 regulatory pathway participates in the activity of DACH-acetato-Pt may represent a potentially important development for clinical therapy of subset of platinum-resistant ovarian tumors with wild-type p53 gene status. These results provide evidence for the novelty of DACH-acetato-Pt and endorse the development of this analogue for clinical trials.

ACKNOWLEDGMENTS

We thank Drs. Neely Atkinson, Jon Weiner, and Wei Zhang for helpful discussions and Ruth LaPushin, Long Nguyen, and Gerald Thai for expert technical assistance.

REFERENCES

Expression of $p53$ in Cisplatin-resistant Ovarian Cancer Cell Lines: Modulation with the Novel Platinum Analogue (1R, 2R-Diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV)


Updated version  Access the most recent version of this article at: http://clincancerres.aacrjournals.org/content/5/3/655

Cited articles  This article cites 55 articles, 24 of which you can access for free at: http://clincancerres.aacrjournals.org/content/5/3/655.full#ref-list-1

Citing articles  This article has been cited by 6 HighWire-hosted articles. Access the articles at: http://clincancerres.aacrjournals.org/content/5/3/655.full#related-urls

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.